AnaptysBio (ANAB) was a big mover in the prior session on above-average volume, but the latest trend in earnings estimate revisions suggests the stock may struggle to extend gains near term. The article does not cite any new operating results or guidance, but highlights a potentially negative analyst-estimate backdrop for the biotech name.
AnaptysBio (ANAB) was a big mover in the prior session on above-average volume, but the latest trend in earnings estimate revisions suggests the stock may struggle to extend gains near term. The article does not cite any new operating results or guidance, but highlights a potentially negative analyst-estimate backdrop for the biotech name.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
